These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19121766)

  • 1. Clinical implications of elevated asymmetric dimethylarginine in chronic kidney disease and end-stage renal disease.
    Mallamaci F; Zoccali C
    J Ren Nutr; 2009 Jan; 19(1):25-8. PubMed ID: 19121766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?
    Kielstein JT; Zoccali C
    Am J Kidney Dis; 2005 Aug; 46(2):186-202. PubMed ID: 16112037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymmetric dimethylarginine: a cardiovascular risk factor in renal disease?
    Fliser D; Kielstein JT; Haller H; Bode-Böger SM
    Kidney Int Suppl; 2003 May; (84):S37-40. PubMed ID: 12694305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease.
    Alsagaff MY; Thaha M; Aminuddin M; Yogiarto RM; Yogiantoro M; Tomino Y
    J Int Med Res; 2012; 40(1):340-9. PubMed ID: 22429374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move.
    Zoccali C
    J Hypertens; 2006 Apr; 24(4):611-9. PubMed ID: 16531785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.
    Kumagai H; Sakurai M; Takita T; Maruyama Y; Uno S; Ikegaya N; Kato A; Hishida A
    Am J Kidney Dis; 2006 Nov; 48(5):797-805. PubMed ID: 17059999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease.
    Zoccali C
    Blood Purif; 2002; 20(5):469-72. PubMed ID: 12207095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure.
    Nanayakkara PW; Teerlink T; Stehouwer CD; Allajar D; Spijkerman A; Schalkwijk C; ter Wee PM; van Guldener C
    Kidney Int; 2005 Nov; 68(5):2230-6. PubMed ID: 16221223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.
    Nanayakkara PW; Kiefte-de Jong JC; ter Wee PM; Stehouwer CD; van Ittersum FJ; Olthof MR; Teerlink T; Twisk JW; van Guldener C; Smulders YM
    Am J Kidney Dis; 2009 Jan; 53(1):41-50. PubMed ID: 18786751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding.
    Kielstein JT; Böger RH; Bode-Böger SM; Martens-Lobenhoffer J; Lonnemann G; Frölich JC; Haller H; Fliser D
    Clin Nephrol; 2004 Oct; 62(4):295-300. PubMed ID: 15524060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
    Busch M; Fleck C; Wolf G; Stein G
    Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study.
    Aucella F; Maas R; Vigilante M; Tripepi G; Schwedhelm E; Margaglione M; Gesualdo L; Boeger R; Zoccali C
    Atherosclerosis; 2009 Dec; 207(2):541-5. PubMed ID: 19501358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis.
    Koyama K; Ito A; Yamamoto J; Nishio T; Kajikuri J; Dohi Y; Ohte N; Sano A; Nakamura H; Kumagai H; Itoh T
    Am J Kidney Dis; 2010 Jun; 55(6):1069-78. PubMed ID: 20430500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.
    Fliser D; Kronenberg F; Kielstein JT; Morath C; Bode-Böger SM; Haller H; Ritz E
    J Am Soc Nephrol; 2005 Aug; 16(8):2456-61. PubMed ID: 15930091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease.
    van Guldener C; Nanayakkara PW; Stehouwer CD
    Clin Chem Lab Med; 2007; 45(12):1683-7. PubMed ID: 17937610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymmetric dimethylarginine and symmetric dimethylarginine: axis of evil or useful alliance?
    Kielstein JT; Fliser D; Veldink H
    Semin Dial; 2009; 22(4):346-50. PubMed ID: 19708979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relations between concentrations of asymmetric dimethylarginine and neopterin as potential risk factors for cardiovascular diseases in haemodialysis-treated patients.
    Avci E; Coskun S; Cakir E; Kurt Y; Ozgur Akgul E; Bilgi C
    Ren Fail; 2008; 30(8):784-90. PubMed ID: 18791952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Level of asymmetric dimethylarginine and carotid atherosclerosis in patients with chronic kidney disease.
    Zhang WR; Hou FF; Ning JP; Yang XB; Wu Q; Tao LJ; Chen BM; Li HY; Chang L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):621-8. PubMed ID: 17062918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arginine, dimethylated arginine and homoarginine in relation to cardiovascular risk in patients with moderate chronic kidney disease.
    Hov GG; Aasarød KI; Sagen E; Åsberg A
    Clin Biochem; 2015 Jul; 48(10-11):646-51. PubMed ID: 25828044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Atherosclerosis and uremia: signifance of non-traditional risk factors].
    Hörl WH
    Wien Klin Wochenschr; 2003 Apr; 115(7-8):220-34. PubMed ID: 12778774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.